Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6871869rdf:typepubmed:Citationlld:pubmed
pubmed-article:6871869lifeskim:mentionsumls-concept:C0678222lld:lifeskim
pubmed-article:6871869lifeskim:mentionsumls-concept:C0003962lld:lifeskim
pubmed-article:6871869lifeskim:mentionsumls-concept:C0543482lld:lifeskim
pubmed-article:6871869lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:6871869pubmed:issue9lld:pubmed
pubmed-article:6871869pubmed:dateCreated1983-9-23lld:pubmed
pubmed-article:6871869pubmed:abstractTextThe TA3-St/ticol ascites cell (I), immunoselected from the strain-specific TA3-St mammary carcinoma ascites cell of the strain A mouse for decreased H-2a antibody-binding capacity, underwent a spontaneous transition in vivo to a new cell line, TA3-St/ticol/-A (II). Line II was more allotransplantable than was the parental line (line I), and its absorptive capacity for anti-H-2a antibody was manyfold less than line I. Disruption of line II cells by lyophilization did not increase the absorptive capacity, in contrast to its marked enhancement in the TA3-Ha ascites cell under similar conditions. An explanation for the enhanced allotransplantability of line II may be related to either a loss of H-2a antigens or altered macromolecular structures at the cell surface: sialic acid, consisting of 93% N-glycolylneuraminic acid for line II and 9% for line I; altered chemical structures of cell surface glycoproteins, particularly a high-molecular-weight glycoprotein present in much greater proportion in line II than in line I; a macromolecular complex released by a protease from line I, but not line II; and I being agglutinable by concanavalin A, but not line II. Electron microscopy showed line II to be more pleomorphic and less rounded than was line I. Under high-resolution electron microscopy, the cell surfaces of both allotransplantable cells, lines II and I, exhibited thin filamentous material, material not observed at the surface of the nonallotransplantable TA3-St ascites cell.lld:pubmed
pubmed-article:6871869pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6871869pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6871869pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6871869pubmed:languageenglld:pubmed
pubmed-article:6871869pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6871869pubmed:citationSubsetIMlld:pubmed
pubmed-article:6871869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6871869pubmed:statusMEDLINElld:pubmed
pubmed-article:6871869pubmed:monthSeplld:pubmed
pubmed-article:6871869pubmed:issn0008-5472lld:pubmed
pubmed-article:6871869pubmed:authorpubmed-author:KleinGGlld:pubmed
pubmed-article:6871869pubmed:authorpubmed-author:JeanlozR WRWlld:pubmed
pubmed-article:6871869pubmed:authorpubmed-author:CodingtonJ...lld:pubmed
pubmed-article:6871869pubmed:authorpubmed-author:SilberCClld:pubmed
pubmed-article:6871869pubmed:authorpubmed-author:MillerS CSClld:pubmed
pubmed-article:6871869pubmed:authorpubmed-author:DalianisTTlld:pubmed
pubmed-article:6871869pubmed:authorpubmed-author:DarbyD MDMlld:pubmed
pubmed-article:6871869pubmed:authorpubmed-author:LIMT HTHlld:pubmed
pubmed-article:6871869pubmed:authorpubmed-author:LampertL ALAlld:pubmed
pubmed-article:6871869pubmed:issnTypePrintlld:pubmed
pubmed-article:6871869pubmed:volume43lld:pubmed
pubmed-article:6871869pubmed:ownerNLMlld:pubmed
pubmed-article:6871869pubmed:authorsCompleteYlld:pubmed
pubmed-article:6871869pubmed:pagination4364-72lld:pubmed
pubmed-article:6871869pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:meshHeadingpubmed-meshheading:6871869-...lld:pubmed
pubmed-article:6871869pubmed:year1983lld:pubmed
pubmed-article:6871869pubmed:articleTitlePhysicochemical and morphological characterization of a new allotransplantable mammary carcinoma ascites subline, TA3-St/ticol/-A.lld:pubmed
pubmed-article:6871869pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6871869pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:6871869pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:6871869pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed